Valuation: Capricor Therapeutics, Inc.

Market Cap 366M 313M 293M 268M 504M 34.99B 510M 3.46B 1.35B 17.58B 1.37B 1.34B 58.14B P/E 2026 *
-2.83x
P/E 2027 * -3.8x
Enterprise Value 366M 313M 293M 268M 504M 34.99B 510M 3.46B 1.35B 17.58B 1.37B 1.34B 58.14B EV / Sales 2026 *
23.1x
EV / Sales 2027 * 8.46x
Free-Float
90.56%
Yield 2026 *
-
Yield 2027 * -
1 day+2.86%
1 week-5.41%
Current month+63.38%
1 month-68.28%
3 months-78.21%
6 months-77.43%
Current year-78.21%
1 week 6.01
Extreme 6.01
8.29
1 month 2.96
Extreme 2.96
8.29
Current year 2.96
Extreme 2.96
36.82
1 year 2.96
Extreme 2.96
40.37
3 years 2.68
Extreme 2.68
40.37
5 years 2.56
Extreme 2.56
40.37
10 years 0.88
Extreme 0.88
42.5
Manager TitleAgeSince
Chief Executive Officer 62 19/11/2013
Director of Finance/CFO 40 31/12/2017
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Chairman 70 31/10/2013
Director/Board Member 68 19/11/2013
Director/Board Member 79 19/11/2013
Date Insider Type Main position Quantity % Market Cap.
02/04/26 Fiscal year

Director

22,587 0.0393%
05/01/26 Free

General Counsel

45,000 0.0827%
05/01/26 Free

Director

15,500 0.0285%
Change 5-day change 1-year change 3-year change Capi.($)
-7.97%-5.41%-11.41%-16.63% 366M
-3.00%+2.27%+73.26%+113.08% 72.12B
-2.68%+2.64%+48.78%+88.45% 65.85B
+5.12%+25.22%+5.13%-5.23% 29.28B
+0.55%+1.64%-4.63%+469.35% 27.47B
-4.71%+5.29%+46.03%+8.97% 26.7B
-2.14%+0.14%+33.82%-18.52% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
-2.79%+0.10%+11.32%+549.69% 16.4B
+0.73%+5.54%+39.99%+148.64% 13.4B
Average -0.42%+6.99%+49.37%+172.67% 28.99B
Weighted average by Cap. -1.37%+9.46%+54.24%+154.12%

Financials

2026 *2027 *
Net sales 15.82M 13.55M 12.68M 11.61M 21.79M 1.51B 22.07M 150M 58.43M 760M 59.41M 58.12M 2.52B 43.24M 37.04M 34.65M 31.72M 59.53M 4.14B 60.32M 409M 160M 2.08B 162M 159M 6.87B
Net income -129M -111M -103M -94.73M -178M -12.35B -180M -1.22B -477M -6.21B -485M -474M -20.53B -99.36M -85.11M -79.64M -72.9M -137M -9.51B -139M -941M -367M -4.78B -373M -365M -15.8B
Net Debt - -
Logo Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program focuses on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, Deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. The clinical development program for Deramiocel has focused primarily on adolescents and young adults with DMD, including many patients who are non-ambulatory and experiencing progressive cardiac and skeletal muscle decline. Its StealthX exosome platform program consists of engineered exosomes for vaccine and therapeutic development. The StealthX vaccine is a proprietary vaccine developed internally utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
Employees
231
Date Price Change Volume
21/08/26 US$6.290 -7.97% 8,361,148
20/08/26 US$6.835 -14.35% 8,108,942
19/08/26 US$7.980 +12.71% 8,565,517
18/08/26 US$7.080 -4.97% 8,538,983
17/08/26 US$7.450 +12.03% 19,218,779
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
6.290USD
Average target price
10.50USD
Spread / Average Target
+66.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPR Stock